IGHE and asthma: The clinical observations described above, particularly efficacy of omalizumab in reducing asthma exacerbations (49, 50, 116, 127, 129), strongly support the pathogenic role of IgE-bound mast cells, pDCs, and cDCs to RV-induced asthma exacerbation (Figure 1).